COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis | The Medical Letter Inc.
Overlooked Treatments
Monoclonal Antibody Authorized to Protect At-Risk People From COVID-19
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
Plasma taurine level is linked to symptom burden and clinical outcomes in post-COVID condition
Researchers identify amino acid that may play a key role for predicting and treating long COVID
Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study
From a Grassroots Survey to Long Covid Treatment Trials
Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations
Narrative Service
Americans Don’t Get to Have the Best New COVID Drug
Further patients benefit from drug against Long COVID
Long COVID: Study Says Synbiotic Drug That Alters Gut Microbiome Relieves Multiple Symptoms
NIH Launches Trials for Long COVID Treatment Breakthroughs
Intravenous immunoglobulin as a potential treatment for long COVID
Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection
Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review - PubMed
Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms
Clinical and CSF single-cell profiling of post-COVID-19 cognitive impairment
Interferon-λ treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity
Long COVID Looks Like Acute Infection in the Brain
Frontiers | Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)
Study Details | Antiviral Clinical Trial for Long Covid-19 | ClinicalTrials.gov
(16) Post-Viral Trials News (@postviraltrials) / X
RECOVER Clinical Trials | Home
Monoclonal antibody levels and protection from COVID-19
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro
Human Immunodeficiency Virus Status, Tenofovir Exposure, and the Risk of Poor Coronavirus Disease 19 Outcomes: Real-World Analysis From 6 United States Cohorts Before Vaccine Rollout | Clinical Infectious Diseases | Oxford Academic